www.kcameetings.org Open in urlscan Pro
2606:4700:3033::ac43:c3dc  Public Scan

Form analysis
1 forms found in the DOM

GET https://www.kcameetings.org/

<form id="gecko-search-form" class="nav-search" method="get" action="https://www.kcameetings.org/">
  <input class="form-control required" name="s" placeholder="Search...">
  <button class="search-icon"><span class="pe-7s-search"></span></button>
</form>

Text Content

 * Contact
 * Newsletter Signup
 * Donate

 * About
 * IKCS: North America
 * IKCS: Europe
 * Past Events
 * Contact

 * 


 * About
 * IKCS: North America
 * IKCS: Europe
 * Past Events
 * Contact


2022 IKCS: NORTH AMERICA

IKCS: North America
November 4-5, 2022

Hyatt Regency Austin
Austin, Texas, USA




REGISTER AND BOOK HOTEL BY SEPTEMBER 21 FOR THE BEST RATES!


REGISTER TODAY
BOOK HOTEL
VIEW PROGRAM AT A GLANCE
VIEW PROGRAM AND SPEAKERS- INCLUDING ORAL ABSTRACT TITLES
POSTER TITLES NOW AVAILABLE



IMPORTANT DATES

Review the important dates below for 2022 IKCS: North America

Abstract Submissions Open Now Open- May 2022Program At a Glance AvailableNow
Available- May 2022 Registration Opens Now Open- May 2022 Hotel Booking Opens
Now Open- May 2022Program Details and Speakers ReleasedNow Available- June
2022Abstract Submission Deadline
(all complete Regular, TPS, and Case Report submissions, and all LBA
Placeholders due at this time)August 2, 2022 at 11:59 PM PDTLBA Submission
Deadline (LBA Placeholder required by August 2 deadline)August 31, 2022 at 12:00
PM (Noon) PDT (placeholder required by August 2, 2022)Abstract Notifications
Sent to Lead AuthorsEarly September 2022 Early Registration Deadline September
21, 2022 at 11:59 PM PDT Abstract Titles ReleasedMid-September 2022Presentation
Slides DueSeptember 19, 2022Abstract Withdrawal Deadline
(Withdrawal requests must be submitted by the Lead Author to
meetings@kidneycancer.org) September 30, 2022Poster Uploads DueOctober 21,
2022Abstracts Released and Hybrid Meeting Platform AvailableNovember 1, 2022 at
5:00 PM ETDeadline to cancel Hotel Reservations without fees48 hours prior to
check-inMeeting DatesNovember 4-5, 2022






REGISTRATION, HOTEL, AND TRAVEL INFORMATION


REGISTRATION

REGISTRATION
BOOK HOTEL

TRAVEL INFORMATION
HEALTH AND SAFETY INFORMATION

Review Registration Rates and Categories below.

CategoryEarly Registration Rate (Register by September 21, 2022 at 11:59 PM
PDT)Regular Registration Rate (After September 21, 2022)In-person
Physician/Scientist$375$500Virtual Only Physician/Scientist$300$400Group
In-person Physician/Scientist (this rate includes 1 in-person
Physician/Scientist registration and 5 virtual Physician/Scientist
registrations)$550$700In-person Allied Health Professional$260$350Virtual Only
Allied Health Professional$210$280In-person Physician In-Training$260$350Virtual
Only Physician In-Training$210$280In-person
Patient/Advocate/CaregiverComplimentary* $50Virtual Only
Patient/Advocate/CaregiverComplimentary*Complimentary*In-person
Industry$480$650Virtual Only Industry$390$520In-person
MediaComplimentary**Complimentary**Virtual Only
MediaComplimentary**Complimentary**

*If you are a Patient, Advocate, or Caregiver please contact
meetings@kidneycancer.org with your interest in attending IKCS. This
Registration category is reserved for Patients, Advocates, and Caregivers who do
not meet one of the other registration categories.

**If you are a Media employee interested in attending IKCS, please contact
meetings@kidneycancer.org with your interest and plan for meeting coverage. This
Registration category is reserved only for Media.


HOTEL ACCOMMODATIONS

Meeting Venue: The Hyatt Regency Austin Texas
Venue Address: 208 Barton Springs Rd, Austin, TX 78704

Book Your Hotel


HEALTH AND SAFETY

Review Health and Safety Information for the 2022 IKCS: North America meeting.

Health and Safety Information



PROGRAM

View the Preliminary Program at a Glance! Speakers and additional Program
Information now available.

Program and Speakers- Oral Abstract Titles Available Now!
Program at a Glance
Poster Titles Now Available



ABSTRACTS

Abstract Submission- Now Closed
Abstract Submission Guidelines

Follow the guidelines below to submit an abstract to 2022 IKCS: North America.

 * All submitters are required to create a free account with Cadmium to access
   the abstract submitter.
 * Important Deadlines:
   * Abstract Submission Deadline (all submissions including LBA placeholder
     submissions due at this time): AUGUST 2, 2022 AT 11:59 PM PDT
   * LBA Final Data Submission Deadline (final data, results, and conclusions
     for LBA placeholder submissions due at this time): August 31, 2022 at 12:00
     PM (Noon) PDT
     * Additional instructions will be sent to lead authors to complete their
       LBA submissions.
   * Abstract Notifications will be sent to lead authors in September 2022.
   * LBA lead authors will receive abstract notifications in September 2022.
 * Abstract Submission Types:
   * Regular Abstract (All research types and summaries of new, ongoing, and
     updated research relating to kidney cancer will be considered)
   * Trials in Progress Abstract (All research types that are open, enrolling,
     ongoing, and have not reached pre-specified endpoints for analysis.)
   * Late-breaking Data Submission Abstract (Phase I, II, III, or IV trials and
     original, high-impact research that could impact practice and standard of
     care)
   * Case Report (A report of the diagnosis, treatment, and follow up of an
     individual patient)
 * Abstract Sections:
   * Abstract Title: The title should objectively describe the study and should
     not include proprietary drug names.
   * Abstract Text: The abstract text should be no more than 300 words including
     the title and abstract body. Word count does not apply towards spaces,
     authors, and affiliations. All abstracts should be structured into four
     sections:
     * Background
     * Methods
     * Results
     * Conclusions
   * Optional Abstract Graph, Illustration, or Table: One brief graph,
     illustration, or table is permitted.
   * Authors: The maximum number of authors permitted is 20.
     * Pharmaceutical industry authors are allowed to present abstracts in
       non-CME sessions (Poster Sessions). If an abstract is selected for
       presentation in a CME-session, and the presenter has financial
       relationships with ACCME-defined ineligible companies, an alternate
       presenter must be identified. A non-named author can present a poster if
       written permission is provided by the lead author to
       meetings@kidneycancer.org.
   * Conflict of Interest Disclosure: Presenting authors must submit a Conflict
     of Interest disclosure identifying financial relationships with
     ACCME-defined ineligible companies. Co-authors do not need to submit a COI
     Disclosure.
 * Abstract Policies
   * Confidentiality Policy: Abstracts are confidential at the time of
     submission. KCA will release full abstracts on November 1, 2022 leading up
     to the meeting.
   * Abstract Supplement: Abstracts presented at IKCS: North America are
     published in a supplement of the Kidney Cancer Journal, the official
     journal of the KCA.
   * KCJ Open Access Policy
   * Permissions Policy
   * Abstract Presentation Ownership: Abstract Presentations (PPT slides and
     Posters) are owned by the author and will not be published/printed by
     KCA/KCJ.

Abstract Submission Categories

Abstracts in the following categories will be considered for presentation:

 * Basic Science
 * Disparities in Cancer, Care, and Access
 * Diagnostics
 * Financial Toxicity- Care Delivery/Health Outcomes
 * Imaging
 * Patient-reported Outcomes
 * Post-treatment Surveillance
 * Prevention and Screening
 * Quality of Care and Quality Improvement
 * Real-World Evidence
 * Survivorship
 * Treatment Toxicities and Symptom Management
 * Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional
   Radiology, Urology, Medical Oncology, etc.)
 * Therapeutics (Local- Primary and Metastatis)
 * Tumor Biology, Biomarkers, and Pathology
 * Other

Late-breaking Data Submission Guidelines

Abstracts submitted in this category are Phase I-IV trials, or original research
that could impact practice and standard of care. LBA Abstracts should be studies
where results and conclusions are not yet available by the August 2 deadline,
but will be available by the August 31, 2022 12:00 PM (Noon) PDT deadline.

Abstracts submitted in this category must have a placeholder submission (all
components except for Results and Conclusions sections) received by the August
2, 2022 11:59 PM PDT abstract submission deadline.

Lead authors will receive separate instructions to complete LBA placeholder
submissions by the August 31, 2022 LBA deadline.

Trials in Progress Abstract Submission Guidelines

Abstracts submitted in this category are ongoing and should not include data,
results, nor conclusions.

TPS abstracts are open, enrolling, or ongoing and have not reached any
protocol-specific endpoints for analysis, and consequently will only require the
completion of the Background and Methods sections.

Abstracts in all phases of clinical research (I, II, III, IV) may be submitted.

Abstract Review and Selection Process

Abstracts will be reviewed by the IKCS: North America Scientific Planning
Committee. Abstract notifications will be sent to lead authors in September
2022.

Abstract-Associated Awards- New for 2022

IKCS: North America Merit Awards

Merit Awards are given to early-career abstract authors of high-quality
submitted abstracts. To apply for a Merit Award, the presenting author should
select “Yes” to the question “would you like to apply for a merit award?” The
presenting author is required to upload a CV/Resume and a Letter of Support from
their training program supervisor substantiating the applicant’s good standing
in their training program.

Merit Award Eligibility Requirements:
– Must be enrolled in a doctorate level program or have a doctorate-level degree
(MD, PhD, PharmD, etc.) completed at the time of submission
– Must be enrolled and in good standing in an oncology or urology training
program, fellowship, or post-doctoral researcher position
– Must upload a CV/Resume and Letter of Support showing participation and good
standing in training program

The IKCS Scientific Planning Committee will select recipients to receive a merit
award for the best original submissions.
*Please note: Trials in Progress presentations will not be eligible to receive a
merit award.

 * First place: $500 USD and complimentary meeting registration
 * Second place: $250 USD and complimentary meeting registration
 * Third place: $100 USD and complimentary meeting registration

Abstract Presenter Guidelines (Oral and Poster Presentation Guidelines)

All accepted abstracts and lead authors are requested to present in-person at
2022 IKCS: North America in Austin, Texas. Accepted abstracts will be displayed
at the live meeting and electronic versions will be available online.

All Abstract Presenters must register for the conference.

All accepted abstracts will be published in the Kidney Cancer Journal, the
official journal of the Kidney Cancer Association. KCJ Open Access Policy

ORAL ABSTRACT PRESENTER GUIDELINES

 * Presentation Format: Oral Abstract Presenters should prepare a 7-minute PPT
   presentation
 * Slide Upload Deadline: PPT slides are due in the presenter portal by
   September 19, 2022. We will try our best to process late files, however,
   files received after this date cannot be guaranteed inclusion in the
   conference platform.
 * Download the PPT slide template
 * Conflict of Interest Disclosure: Oral Abstract Presentations must include in
   a COI Disclosure slide.
 * Withdrawal Deadline: All withdrawal requests must be sent in writing from the
   first author to meetings@kidneycancer.org by September 30, 2022. Requests
   received after this date cannot be guaranteed removal from the program.
 * Corresponding Poster: Oral Abstract presenters should NOT prepare a poster.
   There is no poster component related to an Oral presentation.



POSTER PRESENTER GUIDELINES

 * Poster Presenters should prepare a PDF and printed poster. Attendees will
   have the opportunity to visit posters in-person onsite and view electronic
   versions online.
 * ePoster Deadline: Presenters should upload a PDF poster to the Speaker Portal
   by October 21, 2022. We will try our best to process late files, however,
   files received after this date cannot be guaranteed inclusion in the
   conference platform.
 * Printed Posters: Poster Presenters should bring a printed poster onsite to
   hang on an assigned poster board for the duration of the meeting.
 * Size: Printed posters should not exceed 42 inches by 42 inches (106 cm by 106
   cm). There will be 2 posters per board side. Poster hanging materials will be
   provided onsite.
 * Printing: Poster Presenters should arrange their own poster printing and
   carry their poster onsite. If a Poster Presenter is unable to attend
   in-person, they should arrange for a colleague to carry the poster onsite or
   contact KCA at meetings@kidneycancer.org to obtain shipping information to
   send the poster to the meeting.
 * KCA is not responsible for costs associated with printing and shipping
   posters.
 * Template: No specific Poster Template is required.
 * Withdrawal Deadline: All withdrawal requests must be sent in writing from the
   first author to meetings@kidneycancer.org by September 30, 2022. Requests
   received after this date cannot be guaranteed removal from the program.

Abstract Release Information

Abstract texts will be released on the hybrid meeting platform on November 1,
2022 at 5:00 PM ET.

Poster Presentations will become available beginning November 4, 2022. PDF
versions of presentation slides will become available during the specific
session for the presentation.

Additionally, all accepted abstracts will be published in the Kidney Cancer
Journal, the official journal of the Kidney Cancer Association. KCJ Open Access
Policy. The Kidney Cancer Journal also publishes an IKCS special issue
supplement which will come out in December 2022.


Questions

Please contact meetings@kidneycancer.org.




CONTINUING MEDICAL EDUCATION (CME) INFORMATION

Continuing Medical Education (CME) Information

Jointly provided by The France Foundation and the Kidney Cancer Association.




Target Audience: This educational activity is intended for medical oncologists
and urologists who treat patients with kidney cancer. Fellows, trainees, nurses,
nurse practitioners, physician assistants, and other healthcare professionals
involved in the management of kidney cancer are invited to participate.

Statement of Need: Education and interaction surrounding the space of renal cell
carcinoma are paramount to improving patient care. This program is targeted to
physicians, advocates, researchers, and care team members to help promote
learning and collaboration for advancement in the renal cancer space.

Educational Learning Activity Objectives: Upon completion of this course, the
participants should be able to:

 * Characterize the various therapies currently available for locally advanced
   and metastatic renal cell carcinoma
 * Identify the novel approaches to non-clear RCC patient management
 * Understand the role of the tumor microenvironment in kidney cancer
 * Discuss how to design biomarker driven clinical trials in kidney cancer

Accreditation Statement:

In support of improving patient care, this activity has been planned and
implemented by The France Foundation and the Kidney Cancer Association. The
France Foundation is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.

Credit Designation:

Physicians: The France Foundation designates this live activity for a maximum of
11.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.

Disclosure Policy: In accordance with ACCME Standards for Commercial Support,
The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that
individuals in a position to control the content of an educational activity
disclose all relevant financial relationships with any commercial interest. TFF
and KCA resolve all conflicts of interest to ensure independence, objectivity,
balance, and scientific rigor in all their educational programs. Furthermore,
TFF and KCA seek to verify that all scientific research referred to, reported,
or used in a CME/CE activity conforms to the generally accepted standards of
experimental design, data collection, and analysis. TFF and KCA are committed to
providing learners with high-quality CME/CE activities that promote improvements
in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The
France Foundation who control content have no relevant financial relationships
to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the
Kidney Cancer Association who control content have no relevant financial
relationships to disclose.

2022 IKCS: North America Planning Committee Disclosures are available here.

Disclosure of Unlabeled Use: TFF and KCA require CME faculty (speakers) to
disclose when products or procedures being discussed are off label, unlabeled,
experimental, and/or investigational, and any limitations on the information
that is presented, such as data that are preliminary, or that represent ongoing
research, interim analyses, and/or unsupported opinion. Faculty in this activity
may discuss information about pharmaceutical agents that is outside of US Food
and Drug Administration approved labeling. This information is intended solely
for continuing medical education and is not intended to promote off-label use of
these medications. TFF and KCA do not recommend the use of any agent outside of
the labeled indications. If you have questions, contact the Medical Affairs
Department of the manufacturer for the most recent prescribing information.

Disclaimer TFF and KCA present this information for educational purposes only.
The content is provided solely by faculty who have been selected because of
recognized expertise in their field. Participants have the professional
responsibility to ensure that products are prescribed and used appropriately on
the basis of their own clinical judgment and accepted standards of care. The
France Foundation, KCA, and the commercial supporters assume no liability for
the information herein.

Contact Information: If you have questions about this CME/CE activity, please
contact The France Foundation at 860-434-1650 or info@francefoundation.com.




IKCS: NORTH AMERICA SCIENTIFIC PLANNING COMMITTEE

Thank you to our 2022 IKCS: North America Planners!


Eric A. Singer, MD, MA, FACS
Rutgers Cancer Institute of New Jersey
Planning Committee Co-Chair
Tian Zhang, MD
UT Southwestern Medical Center
Planning Committee Co-Chair
Maria Carlo, MD
Memorial Sloan Kettering Cancer Center

Kiran Virdee, RN, BSN, CCRN
Memorial Sloan Kettering Cancer Center
Jodi Maranchie, MD
University of Pittsburgh
Vitaly Margulis, MD
UT Southwestern Medical Center
Bradley McGregor, MD
Dana-Farber Cancer Institute
Phillip Pierorazio, MD
Penn Presbyterian Medical Center
Laura Wood, RN, MSN, OCN, Retired
Cleveland Clinic Cancer Institute
Yousef Zakharia, MD, University of Iowa Carver College of Medicine

View 2022 IKCS: North America Planning Committee Disclosures.




SPONSORSHIP AND EXHIBITOR OPPORTUNITIES

Download the 2022 IKCS: North America Sponsorship Prospectus

Please contact meetings@kidneycancer.org for more information.




THANK YOU TO OUR 2022 IKCS: NORTH AMERICA SPONSORS!


DIAMOND LEVEL





GOLD LEVEL






SILVER LEVEL







BRONZE LEVEL









MEDIA PARTNERS

Thank you to our 2022 IKCS: North America Media Partners!





FACULTY PRESENTATION GUIDELINES

Speaker PPT Slide Presentations are due in the Faculty/Speaker Portal by
September 19, 2022.

Download PPT Template
Meeting Format

Meeting Format: 2022 IKCS: North America will be a hybrid event offering
in-person and virtual participation options for meeting attendees. Faculty are
expected to attend in-person in, however, reasonable adjustments may be
considered due to COVID-19 related travel restrictions. Some onsite sessions
will be live-streamed to virtual attendees.

Conflict of Interest Disclosure and Session Preparation Information

Conflict of Interest Disclosure: Confirmation of any faculty invitation requires
agreement to abide by Conflict of Interest procedures in addition to policies
set forth by the Kidney Cancer Association, The France Foundation, and the
Accreditation Council for Continuing Medical Education (ACCME) for content and
presentation. All Faculty are required to submit a full disclosure of financial
interests with commercial entities. All Conflict of Interest Disclosures will be
reviewed by The France Foundation for final approval and participation in the
program. Failure to submit a Conflict of Interest Disclosure will prohibit
participation in the program.

Session Preparation: Speakers should upload their presentation slides by
September 19, 2022. Slides will be reviewed by Session Chairs/Moderators and CME
regulators to ensure compliance with CME guidelines, minimize content overlap
between sessions, and help presentations contribute to a cohesive and
educational session. Speakers may receive recommendations for slide adjustments.
Speakers who are only able to participate virtually will receive instructions to
pre-record their presentations prior to the meeting, along with instructions to
participate in the live panel Q+A at the end of the session.

Download the 2022 IKCS: North America PPT Template

Faculty Benefits: 2022 IKCS: North America Faculty may be eligible for benefits
including Registration, Hotel accommodation, and travel assistance. Faculty will
receive details and instructions for meeting arrangements directly via email. If
you have questions please contact meetings@kidneycancer.org.






© 2022 Kidney Cancer Association. All Rights Reserved. Privacy Policy |
WordPress website by Gecko Designs

 * Facebook
 * Instagram
 * YouTube
 * LinkedIn
 * Twitter